Generic Mycophenolate Mofetil Safety Study for Prophylaxis in de Novo Renal Transplant Patients in Jordan

NCT03517982 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2018-05-08

No results posted yet for this study

Summary

The purpose of this observational study was to assess the safety and efficacy of generic mycophenolate mofetil in de novo renal transplant patients in Jordan where no visits or intervention(s) additional to the daily practice were performed.

Conditions

  • Acute Transplant Rejection in Patients Receiving Allogeneic Renal Transplant

Interventions

DRUG

Mycophenolate Mofetil

Film Coated Tablet, each tablet contains 500mg Mycophenolate Mofetil

Sponsors & Collaborators

  • Hikma Pharmaceuticals LLC

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03517982 on ClinicalTrials.gov